Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis
NCT ID: NCT05240859
Last Updated: 2022-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1600 participants
OBSERVATIONAL
2022-02-22
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
NCT01225393
Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis
NCT04188249
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
NCT01004432
Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis
NCT01078571
Post-marketing Observational Study in Subjects With Rheumatoid Arthritis
NCT00234884
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Geleli
RA patients treated with Geleli
Geleli
Adalimumab Biosimilar
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Geleli
Adalimumab Biosimilar
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants for whom the rheumatologists have decided to initiate Geleli treatment.
* Participants who provide a written informed consent form of participating in this study.
Exclusion Criteria
* History of malignancy.
* Congestive heart failure with NYHA class III or IV.
* Females of childbearing or breastfeeding.
* Participate in other clinical trial within 3 months.
* Allergic to the drugs involved in the study.
* The investigator believes that the patient is not suitable to participate in this study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhanguo Li, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Rheumatology and Immunology, Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-Z-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.